Back to top

earnings-consensus: Archive

Zacks Equity Research

Wall Street Analysts Believe SkyWater Technology (SKYT) Could Rally 34.97%: Here's is How to Trade

The average of price targets set by Wall Street analysts indicates a potential upside of 35% in SkyWater Technology (SKYT). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

SKYTNegative Net Change

Zacks Equity Research

Wall Street Analysts Think Stoke Therapeutics (STOK) Could Surge 132.4%: Read This Before Placing a Bet

The consensus price target hints at a 132.4% upside potential for Stoke Therapeutics (STOK). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

STOKPositive Net Change

Zacks Equity Research

Wall Street Analysts Think Backblaze (BLZE) Could Surge 103.57%: Read This Before Placing a Bet

The average of price targets set by Wall Street analysts indicates a potential upside of 103.6% in Backblaze (BLZE). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

BLZENegative Net Change

Zacks Equity Research

Wall Street Analysts Predict a 310.96% Upside in Candel Therapeutics (CADL): Here's What You Should Know

The mean of analysts' price targets for Candel Therapeutics (CADL) points to a 311% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

CADLNegative Net Change

Zacks Equity Research

Wall Street Analysts See an 114.35% Upside in Immunocore (IMCR): Can the Stock Really Move This High?

The mean of analysts' price targets for Immunocore (IMCR) points to an 114.4% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

IMCRNegative Net Change

Zacks Equity Research

Wall Street Analysts Believe Seres Therapeutics (MCRB) Could Rally 713.09%: Here's is How to Trade

The mean of analysts' price targets for Seres Therapeutics (MCRB) points to a 713.1% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

MCRBPositive Net Change

Zacks Equity Research

Wall Street Analysts Believe Kamada (KMDA) Could Rally 106.56%: Here's is How to Trade

The mean of analysts' price targets for Kamada (KMDA) points to a 106.6% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

KMDANegative Net Change

Zacks Equity Research

Wall Street Analysts Think Zoetis (ZTS) Could Surge 26.18%: Read This Before Placing a Bet

The average of price targets set by Wall Street analysts indicates a potential upside of 26.2% in Zoetis (ZTS). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

ZTSNegative Net Change

Zacks Equity Research

Wall Street Analysts Believe Aris Mining Corporation (ARMN) Could Rally 44.68%: Here's is How to Trade

The average of price targets set by Wall Street analysts indicates a potential upside of 44.7% in Aris Mining Corporation (ARMN). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

ARMNNegative Net Change

Zacks Equity Research

How Much Upside is Left in Vertical Aerospace (EVTL)? Wall Street Analysts Think 81.02%

The average of price targets set by Wall Street analysts indicates a potential upside of 81% in Vertical Aerospace (EVTL). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

EVTLPositive Net Change

Zacks Equity Research

Ross Stores (ROST) Expected to Beat Earnings Estimates: Should You Buy?

Ross Stores (ROST) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

ROSTNegative Net Change TGTNegative Net Change

Zacks Equity Research

StepStone Group Inc. (STEP) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

StepStone Group (STEP) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

STEPNegative Net Change CANNegative Net Change

Zacks Equity Research

Workday (WDAY) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

Workday (WDAY) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

WDAYPositive Net Change ZMNegative Net Change

Zacks Equity Research

Earnings Preview: Deckers (DECK) Q4 Earnings Expected to Decline

Deckers (DECK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

DECKPositive Net Change URBNPositive Net Change

Zacks Equity Research

Intuit (INTU) Reports Next Week: Wall Street Expects Earnings Growth

Intuit (INTU) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

INTUNegative Net Change

Zacks Equity Research

Toronto-Dominion Bank (TD) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

Toronto-Dominion (TD) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

TDNegative Net Change

Zacks Equity Research

Analysts Estimate Advance Auto Parts (AAP) to Report a Decline in Earnings: What to Look Out for

Advance Auto Parts (AAP) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

AAPNegative Net Change

Zacks Equity Research

Silvercorp (SVM) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

Silvercorp (SVM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

SVMNegative Net Change

Zacks Equity Research

Autodesk (ADSK) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

Autodesk (ADSK) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

ADSKPositive Net Change DOMOPositive Net Change

Zacks Equity Research

BJ's Wholesale Club (BJ) Earnings Expected to Grow: Should You Buy?

BJ's (BJ) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

BJNegative Net Change

Zacks Equity Research

Ralph Lauren (RL) Earnings Expected to Grow: Should You Buy?

Ralph Lauren (RL) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

RLPositive Net Change

Zacks Equity Research

Does NovoCure (NVCR) Have the Potential to Rally 105.5% as Wall Street Analysts Expect?

The mean of analysts' price targets for NovoCure (NVCR) points to a 105.5% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

NVCRNegative Net Change

Zacks Equity Research

Wall Street Analysts Think MOONLAKE IMMUNO (MLTX) Could Surge 106.62%: Read This Before Placing a Bet

The consensus price target hints at a 106.6% upside potential for MOONLAKE IMMUNO (MLTX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

MLTXNegative Net Change

Zacks Equity Research

Does Enanta Pharmaceuticals (ENTA) Have the Potential to Rally 189.58% as Wall Street Analysts Expect?

The consensus price target hints at an 189.6% upside potential for Enanta Pharmaceuticals (ENTA). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

ENTAPositive Net Change

Zacks Equity Research

Wall Street Analysts Believe Arcturus Therapeutics (ARCT) Could Rally 503.6%: Here's is How to Trade

The consensus price target hints at a 503.6% upside potential for Arcturus Therapeutics (ARCT). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

ARCTPositive Net Change